157 related articles for article (PubMed ID: 16005217)
1. SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: a novel class of cytotoxic agents for prostate cancer.
Gududuru V; Hurh E; Sullivan J; Dalton JT; Miller DD
Bioorg Med Chem Lett; 2005 Sep; 15(18):4010-3. PubMed ID: 16005217
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer.
Gududuru V; Hurh E; Dalton JT; Miller DD
J Med Chem; 2005 Apr; 48(7):2584-8. PubMed ID: 15801848
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer.
Gududuru V; Hurh E; Dalton JT; Miller DD
Bioorg Med Chem Lett; 2004 Nov; 14(21):5289-93. PubMed ID: 15454213
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer.
Gududuru V; Hurh E; Durgam GG; Hong SS; Sardar VM; Xu H; Dalton JT; Miller DD
Bioorg Med Chem Lett; 2004 Oct; 14(19):4919-23. PubMed ID: 15341952
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma.
Li W; Wang Z; Gududuru V; Zbytek B; Slominski AT; Dalton JT; Miller DD
Anticancer Res; 2007; 27(2):883-8. PubMed ID: 17465215
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
Li W; Lu Y; Wang Z; Dalton JT; Miller DD
Bioorg Med Chem Lett; 2007 Aug; 17(15):4113-7. PubMed ID: 17561392
[TBL] [Abstract][Full Text] [Related]
7. New cytotoxic rosamine derivatives selectively accumulate in the mitochondria of cancer cells.
Lim SH; Wu L; Burgess K; Lee HB
Anticancer Drugs; 2009 Jul; 20(6):461-8. PubMed ID: 19387338
[TBL] [Abstract][Full Text] [Related]
8. Discovery and potency optimization of 2-amino-5-arylmethyl-1,3-thiazole derivatives as potential therapeutic agents for prostate cancer.
Krasavin M; Karapetian R; Konstantinov I; Gezentsvey Y; Bukhryakov K; Godovykh E; Soldatkina O; Lavrovsky Y; Sosnov AV; Gakh AA
Arch Pharm (Weinheim); 2009 Jul; 342(7):420-7. PubMed ID: 19544302
[TBL] [Abstract][Full Text] [Related]
9. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
10. Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents.
Metwally KA; Abdel-Aziz LM; Lashine el-SM; Husseiny MI; Badawy RH
Bioorg Med Chem; 2006 Dec; 14(24):8675-82. PubMed ID: 16949294
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of benzofuran- and 2,3-dihydrobenzofuran-2-carboxylic acid N-(substituted)phenylamide derivatives as anticancer agents and inhibitors of NF-κB.
Choi M; Jo H; Park HJ; Sateesh Kumar A; Lee J; Yun J; Kim Y; Han SB; Jung JK; Cho J; Lee K; Kwak JH; Lee H
Bioorg Med Chem Lett; 2015 Jun; 25(12):2545-9. PubMed ID: 25953156
[TBL] [Abstract][Full Text] [Related]
12. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
[TBL] [Abstract][Full Text] [Related]
13. Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists.
Kuhn CF; Bazin M; Philippe L; Zhang J; Tylaska L; Miret J; Bauer PH
Chem Biol Drug Des; 2007 Sep; 70(3):268-72. PubMed ID: 17718722
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
Lu Y; Wang Z; Li CM; Chen J; Dalton JT; Li W; Miller DD
Bioorg Med Chem; 2010 Jan; 18(2):477-95. PubMed ID: 20056548
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
Glenn MP; Kahnberg P; Boyle GM; Hansford KA; Hans D; Martyn AC; Parsons PG; Fairlie DP
J Med Chem; 2004 Jun; 47(12):2984-94. PubMed ID: 15163181
[TBL] [Abstract][Full Text] [Related]
16. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
[TBL] [Abstract][Full Text] [Related]
17. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
18. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of antitumoral activity of ester and amide derivatives of 2-arylamino-6-trifluoromethyl-3-pyridinecarboxylic acids.
Onnis V; Cocco MT; Lilliu V; Congiu C
Bioorg Med Chem; 2008 Mar; 16(5):2367-78. PubMed ID: 18065230
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles.
Davis MR; Styers TJ; Rodriguez RA; Pan PS; Vasko RC; McAlpine SR
Org Lett; 2008 Jan; 10(2):177-80. PubMed ID: 18095697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
